Jose Manuel Otero Sells 4,666 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) COO Jose Manuel Otero sold 4,666 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $20,903.68. Following the sale, the chief operating officer directly owned 137,482 shares of the company’s stock, valued at approximately $615,919.36. This trade represents a 3.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jose Manuel Otero also recently made the following trade(s):

• On Monday, May 18th, Jose Manuel Otero sold 1,302 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.07, for a total transaction of $6,601.14.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO traded down $0.21 during midday trading on Wednesday, reaching $4.45. 852,557 shares of the stock traded hands, compared to its average volume of 948,339. The stock has a market capitalization of $349.41 million, a P/E ratio of -3.07 and a beta of 1.38. Lexeo Therapeutics, Inc. has a 12 month low of $3.60 and a 12 month high of $10.99. The company has a fifty day moving average of $5.16 and a 200 day moving average of $6.67.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. On average, analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. JPMorgan Chase & Co. lowered their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a report on Thursday, June 25th. Weiss Ratings downgraded Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. Finally, Chardan Capital reissued a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $18.75.

Hedge Funds Weigh In On Lexeo Therapeutics

Several large investors have recently made changes to their positions in the business. Spruce Street Capital LP purchased a new position in Lexeo Therapeutics during the fourth quarter valued at $1,738,000. Avoro Capital Advisors LLC purchased a new stake in shares of Lexeo Therapeutics in the fourth quarter worth $32,769,000. 683 Capital Management LLC increased its holdings in shares of Lexeo Therapeutics by 21.4% during the fourth quarter. 683 Capital Management LLC now owns 1,120,000 shares of the company’s stock valued at $11,122,000 after acquiring an additional 197,338 shares in the last quarter. Orbimed Advisors LLC increased its holdings in shares of Lexeo Therapeutics by 69.5% during the first quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock valued at $20,678,000 after acquiring an additional 1,477,450 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its position in shares of Lexeo Therapeutics by 57.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after purchasing an additional 1,850,211 shares during the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.